Mercury Pharmaceuticals Ltd, Paliperidone Mercury Pharma prolonged-release suspension for injection in pre-filled syringes recall

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 2 medicines recall for Paliperidone 50mg, 75mg, 100mg and 150mg prolonged-release suspension for injection in pre-filled syringes. Mercury Pharmaceuticals Ltd is recalling remaining stock of paliperidone pre-filled syringes as a precautionary measure due to Good Manufacturing Practice (GMP) deficiencies cited during a recent inspection at the finished product manufacturing site.

Mercury Pharmaceuticals Ltd has confirmed that due to the ongoing remedial actions at the finished product manufacturing site, there may be delays in the manufacture of future batches.

Pharmacists are advised to stop supplying the batches immediately. Quarantine all stock and return it to your supplier using your supplier’s approved process.

Where appropriate, healthcare professionals involved in dispensing practices (pharmacy teams, homecare teams etc), should contact patients to advise them to contact their prescriber for a review to ensure that an alternative product is available, without delaying their treatment.

Further information, advice and details of the affected batches can be found on the MHRA website.